On the morning of November 6 (Beijing time), global index provider MSCI announced the results of its November 2025 index review. XTALPI (02228), an innovator in AI and robotics-driven drug and material discovery, has been selected for inclusion in the highly tracked MSCI China Index. The adjustment, based on MSCI's semi-annual index review, will take effect after market close on November 24, 2025.

The MSCI China Index added 26 constituents this round, including resource stocks and technology companies specializing in AI, robotics, semiconductors, and advanced manufacturing. Inclusion in the MSCI China Index automatically qualifies a stock for the MSCI Global Standard Index Series, attracting significant passive fund flows.

As a key benchmark for large- and mid-cap Chinese equities, the MSCI China Index is widely followed by global institutional investors. Constituents are selected based on quantitative criteria such as market capitalization, free float, liquidity, and investability. XTALPI's inclusion reflects its compliance with stringent international standards, affirming its investment value and growth potential in the eyes of global capital markets.

**Building a Unique Tech Platform: Vertical AI Commercialization** XTALPI operates an R&D platform integrating quantum physics, AI, and standardized robotic experimentation. A pioneer in AI for Science, it has partnered with over 300 international corporations, startups, and research institutions. The company achieved profitability in the first half of 2025, with operations spanning pharmaceuticals, energy, agriculture, materials, specialty chemicals, and consumer goods.

Notably, XTALPI is among the few AI platforms securing high-value collaborations in both small-molecule and biologics drug discovery. Fifteen of the world’s top 20 pharmaceutical companies are its clients.

The MSCI China Index inclusion underscores market confidence in XTALPI’s secondary-market performance, fundamentals, and future prospects. The company aims to leverage this milestone to strengthen its core technological capabilities, accelerate commercialization, and deliver sustainable long-term returns to global clients, partners, and investors.